SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug Meetmer who wrote (30)7/31/1996 7:55:00 PM
From: John Metcalf   of 1321
 
Doug is correct about the low side effects and positive results of Pharamcyclics' Lu-tex. They recently presented Phase I results at the American Society of Photobiology Conference in Atlanta. There was one patient (of 16) who developed very of the hands, and one patient developed nausea. No phototoxicity was noted, though maximum tolerated dosage had not yet been reached. 61% of patients treated for breast cancer had complete response, a superb result.

Although the general advance and acceptance of photodynamic therapy is good for all the companies working on it (PCYC, QLTIF, PDTI, and DUSA), it might be more appropriate to start a Pharmacyclics thread.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News